CDC42 and neoplasm: We surveyed data obtained from 408 MIBC tumor samples previously classified into broad molecular phenotypes with distinct median overall survival periods (N, BS, L, LI and LP; [22]) for potentially oncogenic TK alterations, such as amplification and overexpression that might underlie catalytic overactivity, and for coincident overexpression of receptor TKs and their cognate ligands.